Trial Profile
A randomised, double-blind, placebo-controlled, multiple dose, time-lagged cohort, dose-escalation trial, investigating the pharmacodynamics, safety and tolerability, and the pharmacokinetics of PSN357AB in patients with type-2 diabetes.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs ATX 09-002 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors OSI Pharmaceuticals (UK); Prosidion
- 02 Apr 2022 This trial has been completed in Germany (End Date: 12 Sep 2006) according to European Clinical Trials Database record.
- 17 May 2011 New trial record